# CJC-1295 (with DAC)

> Evidence tier A — Controlled human trials · GH & Growth · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/cjc-1295-dac/

Also known as: CJC-1295 with DAC, DAC:GRF

## Quick answers

**What is CJC-1295 (with DAC)?**

A long-acting growth hormone releasing hormone analog with a drug-affinity complex that extends its half-life to several days. Modified GHRH(1-29) analogue with a Drug Affinity Complex (maleimide linker) that binds serum albumin.

**How strong is the evidence for CJC-1295 (with DAC)?**

Tier A (controlled human trials) on the peptidemeta evidence scale. Randomized, placebo-controlled dose studies in healthy adults were published (2006); development was discontinued and it is not approved.

**Is CJC-1295 (with DAC) FDA-approved?**

No. CJC-1295 (with DAC) is not approved by the FDA for any use.

**Is CJC-1295 (with DAC) banned in sport?**

Yes. CJC-1295 (with DAC) is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does CJC-1295 (with DAC) work?**

CJC-1295 DAC is a synthetic GHRH analog with four amino acid substitutions for enzymatic stability plus a drug affinity complex (DAC) that binds albumin, extending the half-life to 6-8 days. It binds the GHRH receptor on pituitary somatotrophs, activating cAMP-PKA signaling to promote sustained GH secretion.

**What is known about the safety of CJC-1295 (with DAC)?**

Phase II trials showed generally well-tolerated profile. Common side effects include injection site reactions, water retention, and transient numbness/tingling.

## Key facts

- **Evidence tier:** A (Controlled human trials)
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular

## Overview

A long-acting growth hormone releasing hormone analog with a drug-affinity complex that extends its half-life to several days. Provides sustained GH elevation with less frequent dosing.

## Mechanism

CJC-1295 DAC is a synthetic GHRH analog with four amino acid substitutions for enzymatic stability plus a drug affinity complex (DAC) that binds albumin, extending the half-life to 6-8 days. It binds the GHRH receptor on pituitary somatotrophs, activating cAMP-PKA signaling to promote sustained GH secretion.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Sustained growth hormone elevation over days
- Improved body composition
- Enhanced recovery and deep sleep
- Increased IGF-1 levels

## Safety & unknowns

Phase II trials showed generally well-tolerated profile. Common side effects include injection site reactions, water retention, and transient numbness/tingling. Sustained GH elevation may carry risks of prolonged IGF-1 increase. Not FDA-approved.

## Studies

- Teichman SL, et al. (2006). *Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults*. Journal of Clinical Endocrinology and Metabolism. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/16352683/
  Human study demonstrating CJC-1295 produces sustained GH and IGF-1 elevations for 6+ days after a single injection.

## Status sources

- [Teichman et al. 2006, J Clin Endocrinol Metab](https://pubmed.ncbi.nlm.nih.gov/16352683/)
- [WADA 2026 Prohibited List](https://www.wada-ama.org/en/prohibited-list)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.